Figure 1: Expression of CD30 transcripts and protein in human EC and ES cells. Figure 2: Expression of CD30 in diploid or karyotypically abnormal hES cell lines. Figure 3: Flow-cytometric analysis of ...

CD30 is a member of the tumor necrosis factor receptor superfamily. It is characteristically expressed in certain hematopoietic malignancies, including anaplastic large cell lymphoma and Hodgkin ...

CD30/Ki-1-positive lymphoproliferative disorders of the skin--clinicopathologic correlation and statistical analysis of 86 cases: a multicentric study from the European Organization for Research and ...

A recent study explored the efficacy of brentuximab vedotin (BV) in patients with high-CD30–expressing non-Hodgkin lymphoma (NHL) to determine who is most likely to benefit. A recent study explored ...

Since the discovery of the CD30 molecule in 1982, progress has been made in the treatment and survival outcomes for patients with CD30-positive disease. Nearly 30 years after this discovery, ...

The results of a preclinical study have identified a biological mechanism that explains why some patients don’t respond to immune checkpoint blockade (ICB) therapy for solid cancer tumors. The study, ...

Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T cell ...

Hodgkin's lymphoma and anaplastic large-cell lymphoma are the two most common tumors expressing CD30. Previous attempts to target the CD30 antigen with monoclonal-based therapies have shown minimal ...

Please provide your email address to receive an email when new articles are posted on . A novel anti-CD30 chimeric antigen receptor T-cell therapy conferred a high rate of durable responses among ...

BEIJING – CAR T specialist Wuhan Bio-Raid Biotechnology Co. Ltd. said its BRD-01, an anti-CD30 CAR T therapy candidate, has been granted IND approval by China’s NMPA. It is the first CD30 candidate to ...